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Abstract 
Background: The apolipoprotein E (APOE) and tau proteins play important roles in the 
pathological development of Alzheimer’s disease (AD). Many studies have shown an 
association between the APOE gene and AD. Association between AD and the newly 
discovered saitohin (STH) gene, nested within the intron of the tau gene, has been 
reported. The present study aimed to elucidate the association between APOE and AD, 
and between STH and AD in our sample.  
 
Methods: The functional polymorphisms, rs429358 and rs7412, in the APOE gene 
(which together define the ε2, ε3, and ε4 alleles), and the Q7R SNP in the STH gene, 
were genotyped in 369 patients with AD and 289 healthy European-Americans. The 
associations between these two genes and AD were analyzed in a case-control design.  
 
Results: Consistent with previously reported results, the frequencies of the APOE ε4 
allele, ε4/ε4 genotype and ε3/ε4 genotype were significantly higher in AD cases than 
controls; the ε4/ε4 genotype frequency was significantly higher in early-onset AD (EOAD) 
than late-onset AD (LOAD); the frequencies of the ε2 allele, ε3 allele, ε3/ε3 genotype 
and ε2/ε3 genotype were significantly lower in AD cases than controls. Positive 
likelihood ratios (LRs+) of APOE alleles and genotypes increased in a linear trend with 
the number of ε4 alleles and decreased in a linear trend with the number of ε2 or ε3 
alleles. There was no significant difference in the STH allele and genotype frequency 
distributions between AD cases and controls. 
 
Conclusions: This study confirmed that the ε4 allele is a dose-response risk factor for 
AD and the ε4/ε4 genotype was associated with a significantly earlier age of onset. 
Moreover, we found that the ε2 allele was a dose-response protective factor for AD and 
the ε3 allele exerted a weaker dose-response protective effect for risk of AD compared 
with ε2. In a clinical setting, APOE genotyping could offer additional biological evidence 
of whether a subject may develop AD, but it is not robust enough to serve as an 
independent screening or predictive test in the diagnosis of AD. STH variation was not 
significantly associated with AD in our sample. 
 
Key Words: Alzheimer’s disease, APOE gene, STH gene, dose effect, positive 




Alzheimer’s disease (AD) is the most common cause of dementia. It is a 
primary neurodegenerative cerebral disease in the elderly, characterized by two 
major histopathologic changes in the brain, i.e., extracellular amyloid plaques 
and intracellular neurofibrillary tangles [1,2]. 
Apolipoprotein E (APOE) is one of the major cholesterol transport proteins. 
It exists in three major isoforms, APOE2, APOE3 and APOE4. The three APOE 
isoforms differ in the 112th and 158th residues of their primary structures (Figure 
1); these differences are classified as SNPs rs429358 and rs7412, respectively. 
The APOE3 protein has higher receptor affinity than the variant types APOE2 
and APOE4. Substitution of the basic amino acid Arg158 in APOE3 by the neutral 
amino acid Cys158 in APOE2 results in the receptor affinity of APOE2 being 
reduced to 2% of that of APOE3 [3]. In the central nervous system, APOE 
mediates the uptake and redistribution of cholesterol, and different APOE 
isoforms modify cholesterol homeostasis by preferentially associating with 
specific lipoprotein particles [4]. The role of APOE in modifying cholesterol 
homeostasis in the brain may contribute to the relationship between APOE and 
AD. Furthermore, APOE exists inside the amyloid plaque, where it can bind to β-
amyloid (Aβ), which is a major component of the plaque [5]. Studies have shown 
that APOE interacts with Aβ to form a stable complex, altering the deposition of 
Aβ and affecting Aβ-induced neurotoxicity [6].  
Moreover, APOE may be involved in Alzheimer’s disease through a tau 
pathway. Studies have indicated that tau plays an important role in the 
physiopathology of Alzheimer’s disease and that an extended haplotype (H1), 
covering the entire tau gene, including a 238 bp insertion in intron 9, is 
associated with AD [2, 7-12], although these observations have not always been 
confirmed by other studies. APOE2 and APOE3 can bind to tau and prevent tau 
from being hyperphosphorylated. Although APOE4 also binds to tau, it cannot 
prevent tau from hyperphosphorylation, but destabilizes tau. The 
hyperphosphorylated tau can decrease tau’s affinity for microtubules and 
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severely disrupt microtubule stability, which has been postulated to be an 
important step in the formation of the paired helical filament (PHF) involved in 
neuronal degeneration. This may be part of the mechanism of APOE’s important 
role in the etiology of AD. 
APOE2, APOE3 and APOE4 are encoded by the ε2, ε3 and ε4 alleles, 
respectively [13]. The roles of these alleles in modulating risk for AD have been 
widely studied. (a) The ε4 allele contributes to the risk for AD across most 
populations [e.g., 14, 15]. (b) AD patients with the ε4 allele have an earlier age-
of-onset than those without the ε4 allele [e.g., 16, 17]. (c) The ε4 allele has a 
significant dose effect on the risk for AD [e.g., 18-20]. (d) The ε2 allele may 
protect individuals from being affected with AD [e.g., 14, 15].  
Saitohin (STH), an intronless gene, has been shown to be nested in the 
intron between exons 9 and 10 of the tau gene, 2.5 kb downstream from exon 9. 
This region is functionally critical due to the splicing of exon 10. The special 
location of the STH gene has prompted investigation into its possible role in AD 
and other neurodegenerative disorders. The A224G polymorphism in the STH 
gene, which causes a glutamine (Q) to arginine (R) substitution at residue 7 
(Q7R), is in linkage disequilibrium with the extended tau H1/H2 haplotype [21, 
22]. That is, the STH Q allele is associated with tau haplotype H1, and the STH R 
allele is associated with haplotype H2. An initial study by Conrad et al. [23] 
demonstrated that the Q7R polymorphism in the STH gene was associated with 
risk for AD. The STH gene has also been associated with autosomal dominant 
frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and Pick’s 
disease [21, 23-25]. Nevertheless, these findings remain controversial [22, 25-29]. 
The purpose of the present study was to elucidate the associations 
between the variants at APOE and STH loci and AD in our samples, and to 
explore the gene-dose effects and evaluate the implications of variation at the 
APOE gene in the diagnosis of AD. 
 
Methods and Materials 
Subjects 
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The sample included 658 European-Americans, including 369 patients with AD 
and 289 healthy controls. The diagnosis of AD was based on criteria of the 
National Institute of Neurological and Communicative Disorders and Stroke and 
Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA) [30]. 
The AD cases were divided into an early-onset (EOAD) group and a late-onset 
(LOAD) group based on an age-of-onset of 70 years [27, 29]. Each subject was 
evaluated for an approximate date of AD onset, based on careful review of 
medical records and detailed interviews with one or more primary caregivers. The 
date of onset was operationally defined as the date at which the “earliest definite 
AD symptom” appeared. The mean age of AD patients was 73.6±8.4 years 
(range: 51.8 to 92.7); the mean age-of-onset was 69.3±8.3 years (range: 44.6 to 
86.7; 3 subjects unknown); 143 were male, 226 were female; 180 had positive 
family history (FH+), 184 had negative family history (FH–), and 5 had unknown 
family history. Family history of AD was assessed using the Alzheimer Dementia 
Risk Questionnaire (ADRQ) [31] and the Dementia Questionnaire (DQ) [32]. 
Family history was considered positive if at least one first-degree relative met 
criteria for primary degenerative dementia. No cases suggestive of autosomal 
dominant transmission were identified.  
There were two sets of control subjects who were differentiated based on 
the method of ascertainment. The first set of healthy controls (n=185) was 
recruited through advertisements in the community.  They were screened using 
the Structured Clinical Interview for DSM-III-R (SCID), the Computerized 
Diagnostic Interview Schedule for DSM-III-R (C-DIS-R), the Schedule for 
Affective Disorders and Schizophrenia (SADS) [33], or an unstructured interview, 
to exclude major Axis I disorders, including substance dependence, psychotic 
disorders, mood disorders, anxiety disorders and dementia. Their mean age was 
28.1±9.1 years (range: 18.0 to 52.0); 81 were male and 104 were female. The 
second set of healthy controls (n=104) was recruited primarily from among 
spouses of AD patients. Their mean age was 63.3±16.3 years (range: 21.1 to 
87.5); 49 were male and 55 were female. They were evaluated as being in 
generally good medical health for their age on the basis of a comprehensive 
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evaluation that included medical history, physical and neurological examinations, 
serum chemistries, thyroid function studies, complete blood count, B12, folate, 
VDRL, urinalysis, electrocardiogram, and brain MRI or CT. The second set of 
controls was also required to have no significant evidence of cognitive 
impairment, as indicated by a Mini-Mental State Examination (MMSE) [34] score 
> 27. Subjects were recruited at Yale University School of Medicine, the 
University of Connecticut Health Center, or the VA Connecticut Healthcare 
System, West Haven Campus. Informed consent was obtained from all the 
patients and the controls. This study was performed after approval by the 
appropriate Institutional Review Boards (IRBs). 
 
Genotyping 
Genomic DNA was extracted from peripheral blood by standard methods. The 
region flanking the two target markers within exon 5 of APOE, rs429358 and 
rs7412, was amplified by a single polymerase chain reaction (PCR) using the 
following primers [35]: APOE-A: 5'-CGGGCACGGCTGTCCAAGGAG-3' and 
APOE-C: 5'-CACGCGGCCCTGTTCCACgAG-3' (g is mismatched). PCR was 
performed in a final volume of 10 µl with 1× PC2 buffer (Ab Peptides, Inc., St. 
Louis, MO), 1M betaine, 0.5 units of KlenTaq polymerase (Ab Peptides, Inc., St. 
Louis, MO) and 10 ng DNA. PCR conditions were set as follows: 95oC for 5 min; 
35 cycles of 95oC for 30 s, 64oC for 30 s, and 72oC for 30 s. The genotypes were 
analyzed on 5% metaphor agarose gel after digestion with HhaI (New England 
Biolabs Inc., Beverly, MA). The size of the PCR product was 303 bp, within which 
there are eight constant HhaI cleavage sites (GCG|C) and two variant HhaI 
cleavage sites (see Figure 1).  
The region flanking the Q7R marker in the STH gene was amplified by 
PCR using the primers from the initial study by Conrad et al. [23]. PCR was 
performed in a final volume of 15 µl with 1× PC2 buffer, 1M betaine, 0.75 units of 
KlenTaq polymerase and 25 ng DNA. PCR conditions were set as follows: 95oC 
for 5 min; 30 cycles of 95oC for 30 s, 60oC for 30 s, and 72oC for 30 s. The 
genotypes were analyzed on 3% metaphor agarose gel after digestion with HinfI 
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(New England Biolabs Inc., Beverly, MA). The size of the PCR product was 226 
bp. The R allele (Arginine, CGA) can be cut by HinfI (97bp+74bp+55bp), 
whereas the Q allele (Glutamine, CAA) cannot (171bp+55bp). 
 
Statistical analysis 
The comparisons in allele and genotype frequency distributions between two 
groups were performed with Fisher’s exact test. Bonferroni correction was used 
to adjust the α level of multiple comparisons [36]. 
Positive predictive values (PPVs) were calculated with Bayes’ rule [37]. 
P(AD) was the prior probability of developing AD, i.e., the prevalence of AD (see 
Formula). We used 15% as the estimated prevalence of AD [38]; P(Controls)≈1-
P(AD); P(ε|AD) was allele or genotype frequency in AD cases, and P(ε|Controls) 
was allele or genotype 
frequency in controls. Both 
P(ε|AD) and P(ε|Controls) 
were estimated from the present study; P̂  (AD|ε) was the posterior probability of 
developing AD given a certain allele or genotype. 
Positive likelihood ratios (LRs+) were calculated by dividing the allele or 
genotype frequencies in AD cases by those in controls [39]. For example, if the 
frequency of the ε4/ε4 genotype is 0.139 in AD cases and 0.037 in controls, then 
the LR+ is equal to 0.139/0.037 = 3.757.     
The dose effect of the APOE gene, i.e., the relationship between the risk 
for AD and the number of APOE alleles, was tested by the chi-square test for 
trend using the software EPISTAT [40]. The relationships between the number of 
APOE alleles and their LRs+ were tested with Spearman’s rank correlation 
analysis implemented in SPSS 13.0 (SPSS Inc., Chicago, IL). Gene dose effects 
for APOE were plotted using a polynomial curve-fitting plot method in S-PLUS 
2000 (Mathsoft Engineering & Education, Inc., Cambridge, MA).   
Age, sex, and AD family history are confounders that may cause false 
positive or false negative results. Thus, we used stepwise logistic regression 














APOE and STH alleles, controlling for the effects of the potential confounders. In 
the stepwise logistic regression model, the diagnosis served as the dependent 
variable; the independent variables included the number of APOE ε4 alleles, the 
number of APOE ε2 alleles, the number of STH R alleles, the interaction between 
STH R allele and APOE alleles, age, sex and AD family history. This analysis 
was performed with SPSS 13.0 software.  
 
Results 
      
There was no significant difference in allele frequency distributions, genotype 
frequency distributions or dose effects of APOE and STH gene between our two 
sets of controls, so we combined the two control groups into one larger control 
group. 
 
Associations of APOE alleles and genotypes with Alzheimer’s disease  
The comparisons of allele and genotype frequency distributions between 
AD cases and controls are shown in Tables 1 and 2. The genotype frequency 
distributions in both AD cases and controls were in Hardy-Weinberg equilibrium 
(HWE).  
The overall allele and genotype frequency distributions in AD cases were 
significantly different from those in controls. The frequencies of the ε4 allele, 
ε3/ε4 and ε4/ε4 genotypes were significantly higher in AD cases than in controls 
and the frequencies of the ε2, ε3 alleles, ε2/ε3 and ε3/ε3 genotypes were 
significantly lower in AD cases than in controls. 
We also compared allele and genotype frequencies in AD subgroups 
(EOAD, LOAD, FH+ AD, FH– AD, male AD and female AD) with those in controls. 
The overall allele and genotype frequency distribution in each of the AD 
subgroups was significantly different from that in controls. Specifically, the 
frequencies of the ε4 allele and the ε3/ε4 genotype in each of the AD subgroups, 
and the ε4/ε4 genotype in EOAD, FH+ AD, FH- AD, and female AD were 
significantly higher than those in controls; the frequencies of the ε3 allele and the 
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ε3/ε3 genotype in each of the AD subgroups, and the ε2 allele in EOAD, FH+ AD 
and female AD were significantly lower than those in controls. The genotype 
frequency distributions were significantly different between EOAD and LOAD 
[(the ε4/ε4 genotype frequency in EOAD (0.203) was significantly higher than that 
in LOAD (= 0.082)]. Among these differences, the nominal difference in the 
frequency of the ε2 allele between cases and controls was not statistically 
significant after Bonferroni correction.  
Stepwise logistic regression analyses showed that after adjusting for age, 
sex, and AD family history, the ε4 and ε2 alleles were still significantly associated 
with risk for AD (Pε4 = 0.014, adjusted ORε4 = 1.86, 95% CIε4: 1.13-3.05; Pε2 = 
0.041, adjusted ORε2 = 0.36, 95% CI ε2: 0.13-0.96).  
 
PPVs  and LRs+ of the APOE gene for the diagnosis of AD  
PPVs and LRs+ of APOE alleles and genotypes for AD are listed in Table 3. 
Both PPVs and LRs+ of APOE alleles and genotypes were in the following order: 
ε4/ε4 > ε4 > ε3/ε4 > ε3 > ε2/ε4 > ε3/ε3 > ε2 > ε2/ε3. 
We also compared PPVs for different subtypes of AD. PPVs of the ε4/ε4 
genotype were much higher in EOAD (49.2% vs. 28.1% for LOAD), female AD 
(48.4% vs. 28.9% for male AD) and FH+ AD (43.6% vs. 36.8% for FH– AD).  In 
addition, the PPV for the ε3/ε4 genotype was higher in LOAD (31.1%) than 
EOAD (26.0%). Finally, the PPVs were lower for FH+ AD for the ε2 allele and the 
ε2/ε3 genotype (3.9%, 4.6%, respectively) than for FH– AD (8.0%, 6.1%, 
respectively). 
 
Gene dose effects of the APOE gene on the risk for AD (Table 4 and Figure 2) 
The chi-square test for trend analyses showed that there was a significant 
positive correlation between the number of ε4 alleles and risk for AD and a 
significant negative correlation between the number of ε2 or ε3 alleles and risk 
for AD. 
Similarly, the Spearman’s rank correlation analysis showed that the 
number of APOE alleles was significantly correlated with LR+, which increased 
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linearly with the number of the ε4 alleles (correlation coefficient rε4 = 1.0; slope K 
ε4 = 1.602) and decreased linearly with the number of ε2 or ε3 alleles (correlation 
coefficient rε2 or ε3=-1.0; slope Kε2=-0.543; slope Kε3=-1.122). 
 
Association of the STH gene with AD  
No significant difference in STH allele and genotype frequency 
distributions was found between AD cases and controls.  Even after adjusting for 
potential confounding by the APOE gene, age, sex and AD family history, 
stepwise logistic analyses showed no association of STH alleles or genotypes 
with AD.  
 
Interactive effects between the STH gene and the APOE gene 
Using STH genotypes, we grouped all subjects into QQ, RR and QR 
groups. We then compared APOE allele and genotype frequency distributions in 
these three groups in both cases and controls. No significant difference was 
found for any of the comparisons (data not shown). 
 
Discussion 
 The present study confirmed the well-established association between the 
APOE gene and AD. All three APOE alleles (ε2, ε3 and ε4) showed dose effects 
on the risk for AD, and followed a co-dominant mode of inheritance. We also 
examined, for the first time to our knowledge for a trait in neuropsychiatry, a 
mathematical measure of the predictive value of each APOE allele and genotype 
for AD diagnosis risk. 
In addition to a significant association between the APOE gene and 
Alzheimer’s disease, subgroup analyses revealed an association with subtypes 
based on age of onset, family history, and sex. The ε4 allele, the ε4/ε4 genotype 
and the ε3/ε4 genotype were risk factors for AD; the ε2 allele, the ε3 allele, the 
ε2/ε3 genotype and the ε3/ε3 genotype were protective factors for AD. These 
findings are consistent with those in most previous studies [e.g., 14, 15]. Further 
comparisons among AD subgroups and controls showed that the ε4/ε4 genotype 
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frequency was significantly higher in EOAD than in LOAD and controls, 
suggesting that the ε4/ε4 genotype can significantly reduce the age-of-onset. 
This is consistent with findings in other studies [e.g., 19].  
We also found that the PPV of the ε4/ε4 genotype was significantly higher 
in females (48.4%) than in males (28.9%).  Although the ε4/ε4 genotype 
frequency in female AD cases was significantly higher than in female controls, we 
found no significant difference in males. These results suggest that the ε4/ε4 
genotype is a stronger risk factor for females than for males. This is consistent 
with findings from other studies [e.g., 41-43]. However since sex distributions 
were not well matched between cases and controls, it could also reflect a 
stratification effect by sex. 
Both the chi-square test for trend and the regression analyses revealed 
that the risk for AD increased significantly with the number of ε4 alleles. This is 
also consistent with findings from other studies [e.g., 18]. In addition, we found 
that the risk for AD decreased with the number of ε2 or ε3 alleles. Furthermore, 
the dose of APOE alleles was linearly related to LR+. These results are all 
compatible with those from our allelewise analyses. 
This information is of importance in predicting the development of AD in 
early life. However, not all subjects with the ε4 allele develop AD, nor do all AD 
patients carry the ε4 allele. On the other hand, not all subjects are protected 
against AD by the ε2 and ε3 alleles. Therefore, it is important to estimate the 
probability that these allele carriers will develop AD. We found that the ε4/ε4 
genotype had a PPV of 39.90% and an LR+ of 3.76 for AD. In other words, a 
subject carrying two ε4 alleles has a probability of 39.90% to develop AD. In 
contrast, a subject carrying one ε4 allele and one ε3 allele has a probability of 
28.80% to develop AD, and a subject carrying one ε4 allele and one ε2 allele has 
a probability of 10.82% to develop AD. Based on the interpretation of LRs+ by 
Ebell [39], the presence of APOE alleles can only mildly change the risk for AD, 
despite a highly significant association with AD. This implies that APOE genotype 
testing can provide evidence on whether a subject may develop AD, but it is not 
sufficient as an independent screening or predictive test for the diagnosis of AD 
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[44]. Additionally, we found the following order for both PPVs and LRs+ of APOE 
alleles and genotypes with respect to the diagnosis of AD: ε4/ε4 > ε4 > ε3/ε4 > ε3 
> ε2/ε4 > ε3/ε3 > ε2 > ε2/ε3 (see Table 3). This order shows that: (1) ε4/ε4 > ε4, 
suggesting that the risk for AD increases with the number of ε4 alleles; (2) ε4 > 
ε3/ε4 and ε3/ε4 > AD population prevalence, suggesting that the ε3 allele 
reduces the risk for AD conveyed by the ε4 allele, but the protective effect of ε3 is 
weaker than the risk effect of ε4; (3) ε3/ε3 < ε3, suggesting that the protection 
against AD increases with the number of ε3 alleles; (4) ε3 > ε2/ε3 and ε2 > ε2/ε3, 
suggesting that the protective effect on AD risk for a genotype containing two 
protective alleles is greater than that for a genotype containing only one of the 
protective alleles; (5) ε3 > ε2 and ε3/ε3 > ε2/ε3, suggesting that the ε2 allele is a 
stronger protective factor for AD than the ε3 allele, which is reflected in their 
positions on the Y axis in the figure depicting the dose effect (Figure 2); and (6) 
ε3/ε4 > AD population prevalence, but ε2/ε3 < ε3/ε3 < ε3 < AD population 
prevalence, suggesting that without ε4, the ε3 allele and any genotypes 
containing the ε3 allele cannot increase risk for AD, that is, it is ε4, not ε3, that 
contributes to the increased risk of AD associated with the ε3/ε4 genotype. 
Similarly, the PPV for ε2/ε4 < AD population prevalence (i.e., a protective effect), 
but ε4/ε4 > ε4 > ε3/ε4 > AD population prevalence (i.e., a risk effect), suggesting 
that without ε2, the ε4 allele and any genotypes containing the ε4 allele (e.g., 
ε4/ε4 and ε3/ε4) do not have a protective effect; it is ε2, not ε4, that results in the 
ε2/ε4 genotype having a lower PPV. Taken together, the order of these effects 
suggests that ε4 is a dose-response risk factor for developing AD, ε2 is a dose-
response protective factor, and ε3 is a relatively weaker dose-response 
protective factor. These findings are consistent with the results of our allelewise 
analyses, chi-square tests for trends, and logistic regression analyses. 
There has been debate about whether the presence of a “bad” allele (i.e., 
ε4) or of a “good” allele (ε2 or ε3), or both, contribute to the association between 
APOE and AD. The answer to this question is important for the development of 
specific therapies for AD [45]. Our results tend to show that both the “bad” allele 
(ε4) and the “good” alleles (ε2 and ε3) are involved in the risk for AD, consistent 
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with codominant inheritance. These findings are supported by the evidence from 
studies on the neuropathological processes involved in AD [e.g., 6]. 
Noting both the close interaction between the APOE and the tau proteins 
and the physical proximity of the Tau and STH genes, we investigated the 
correlation between effects of the APOE and STH gene polymorphisms. We 
found no significant interactive effect between these two genes either in cases or 
in controls. This finding was consistent with our regression analysis and the 
studies by Conrad et al. [23] and Peplonska et al. [22]. Thus, the APOE gene 
affects risk for AD through a pathway independent of the STH gene 
polymorphism we queried. 
We also found no associations between STH alleles and AD, even after 
adjusting for potential confounders, including age, sex, and family history. Neither 
the genotype analysis nor the gene-dose analysis showed any association. Our 
results suggest that STH may not be a risk gene for AD. The initial positive 
findings by Conrad et al. [23] may be attributable to sampling bias in the context 
of small sample sizes (51 AD cases; 30 healthy controls). Our sample size (286 
AD cases; 197 healthy controls) is much larger than theirs. Moreover, our 
negative findings are in good agreement with many other studies, which also 
have much larger sample sizes (e.g., 499 AD cases and 402 controls by Verpillat 
et al. [25]; 225 AD cases and 144 controls by Streffer et al. [27]; 200 AD cases 
and 458 controls by Clark et al. [28]; 690 AD families, 903 AD cases and 320 
controls by Oliveira et al. [29]; 100 AD cases and 100 controls by Peplonska et al. 
[22]). Additionally, the Q allele frequency (0.867) in controls in the initial study is 
similar to both controls and cases in our and the other negative studies; but the Q 
allele frequency (0.676) in AD cases is significantly lower than those in cases and 
controls in most of the published studies [22, 25, 27-29]. So far, there has been 
only one study [24] reporting a replicated positive finding between the genotype 
STH RR and AD (p=0.04), but even this positive finding is only nominal and does 
not survive after Bonferroni correction. Therefore, we conclude that the STH 
gene Q7R variation does not play an important role in the pathology of AD.
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Figure 1. HhaI cleavage sites within the APOE amplicon. 1 The residue positions 
are updated in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/). ε2 
allele (haplotype): 130Cys+176Cys (old:112Cys+158Cys) = 91bp+83bp+others 
(≤33bp); ε3 allele (haplotype): 130Cys+176Arg (old:112Cys+158Arg) = 91bp+ 
48bp+35bp+others (≤33bp); ε4 allele (haplotype): 130Arg+176Arg (old:112Arg+ 
158Arg) = 72+48+35+19+others (≤33bp). 
 
Figure 2. Dose effects of APOE gene alleles. X-axis represents the copies of 
alleles (ε2 allele, pink line; ε3 allele, green line; ε4 allele, red line); Y-axis 





Table 1. Distributions of allele frequencies of APOE and STH gene variations in European-American subjects 
                            APOE alleles                            .                        Exact p-values             .                     STH alleles             .   
Exact 
p-value  
         ε2    .         ε3    .         ε4    . Total ε2 ε3 ε4 Total       Q    .       R     . Total   
 f  n f n f n 2N     f n f n 2N   
AD 0.024 17 0.617 443 0.359 258 718 0.001 6.0*10-12 2.4*10-18 1.2*10-18 0.767 439 0.233 133 572 0.345 1 
  EOAD 0.017 6 0.590 203 0.392 135 344 0.002 4.7*10-11 6.8*10-17 2.5*10-17 0.771 216 0.229 64 280 0.506 2 
  LOAD 0.027 10 0.644 237 0.329 121 368 0.022 3.6*10-7 3.1*10-11 5.5*10-11 0.762 218 0.238 68 286 0.348 2 
  FH+ 0.014 5 0.590 204 0.396 137 346 6.8*10-4 4.9*10-11 2.1*10-16 2.3*10-17 0.737 205 0.263 73 278 0.094 2 
  FH– 0.030 11 0.641 232 0.329 119 362 0.051 2.2*10-7 4.1*10-11 1.1*10-10 0.796 226 0.204 58 284 1.000 2 
  Male 0.032 9 0.635 179 0.333 94 282 0.093 3.9*10-5 1.7*10-7 3.9*10-7 0.738 155 0.262 55 210 0.145 3 
  Female 0.018 8 0.606 264 0.376 164 436 0.008 7.0*10-8 9.8*10-12 4.9*10-12 0.785 284 0.215 78 362 1.000 3 
Controls  0.061 30 0.801 394 0.138 68 492     0.794 313 0.206 81 394   
  Male 0.065 15 0.800 184 0.135 31 230     0.805 140 0.195 34 174   
  Female 0.057 15 0.802 210 0.141 37 262     0.786 173 0.214 47 220   
        f, frequency; n, number of alleles; N, number of individuals; 2N, number of chromosomes; AD, Alzheimer’s disease; EOAD, early-onset AD 
(70yrs); LOAD, late-onset AD (>70yrs); Controls, the total controls combining two subgroups through two different diagnostic evaluations. 
      The numbers in  last column denote: 1.Comparing overall AD with controls (α was set at 0.017 for each APOE allele comparison); 2. 
Comparing EOAD, LOAD, FH+ AD and FH– AD with controls respectively (α was set at 0.003 for each APOE allele comparison); 3. Comparing 




Table 2. Distributions of the genotype frequencies of the APOE gene variations in European-American subjects 
                                                    APOE genotypes                                                     .                                              Exact P-values                                    . 
        ε2/ε3 .         ε2/ε4  .        ε3/ε3  .        ε3/ε4  .        ε4/ε4   . Total ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4 Total 
 f N f N f N f N f N N       
AD 0.036 13 0.011 4 0.384 138 0.429 154 0.139 50 359 0.001 0.721 8.1*10-11 3.0*10-10 1.9*10-5 2.1*10-16 
  EOAD 0.029 5 0.006 1 0.390 67 0.372 64 0.203 35 172 0.004 0.653 1.1*10-7 2.9*10-5 5.8*10-8 2.5*10-13 
  LOAD 0.038 7 0.016 3 0.386 71 0.478 88 0.082 15 184 0.010 1.000 3.8*10-8 1.6*10-10 0.056 2.5*10-11 
  FH+ 0.029 5 0.000 0 0.341 59 0.468 81 0.162 28 173 0.004 0.146 2.8*10
-10 9.8*10-10 1.4*10-5 4.1*10-16 
  FH– 0.039 7 0.022 4 0.425 77 0.392 71 0.122 22 181 0.010 0.727 3.3*10-6 3.5*10-6 0.001 6.1*10-9 
  Male 0.043 6 0.021 3 0.390 55 0.447 63 0.099 14 141 0.053 1.000 1.8*10-5 1.8*10-6 0.099 6.3*10-7 
  Female 0.032 7 0.005 1 0.381 83 0.417 91 0.165 36 218 0.015 0.559 1.7*10-6 6.4*10-5 8.7*10-5 8.9*10-10 
EOAD vs. LOAD          0.772 0.624 1.000 0.053 0.001 0.009 
Controls  0.106 26 0.016 4 0.654 161 0.187 46 0.037 9 246       
  Male 0.113 13 0.017 2 0.661 76 0.165 19 0.043 5 115       
 Female 0.099 13 0.015 2 0.649 85 0.206 27 0.031 4 131       
     f, N, AD, EOAD, LOAD, Controls and the comparing methods see Table 1. EOAD vs. LOAD, comparing EOAD and LOAD. α was set at 0.010 (or 0.002) for each 
genotype comparison between overall  AD and controls (or between  AD subgroups and controls), referring to Table 1. ε2/ε3, the genotype consists of allele ε2 and allele ε3; 



















Table 3. Interpretation of PPVs and LRs
+
 of APOE alleles and genotypes 




Significance for diagnosis  
   >10 greatly increasing risk for AD 
   5~10 moderately increasing risk for AD 
ε4/ε4 39.90% 3.76   
ε4 31.50% 2.60 2~5 small increase in risk for AD 
ε3/ε4 28.80% 2.29   
   1~2 minimally increasing risk for AD 
 15.00% (population 
prevalence) 
 1 no change in risk for AD 
ε3 12.00% 0.77 
ε2/ε4 10.82% 0.69 




minimally decreasing risk for AD 
ε2 6.50% 0.39 




small decrease in risk for AD 
   0.1~0.2 moderately decreasing risk for AD 
   <0.1 greatly decreasing risk for AD 
PPV, estimated positive predictive value; LR
+
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 f, N, AD, EOAD, LOAD, Controls, and the comparing methods see Tables 1 and 2.  













test for trend 
Chi-Square 
Table 4. Distributions of the frequencies of the genotypes with ascending APOE allele number 

 
Length (bp)                                 |19+72=91|    |48+35=83| 
HhaI cleavage sites  0       33   49   68            140 158       206     241 248 259 272     303 
                             |------|----|----|-----------|---|--------|-------|----|----|----|------| 
New residue positions
1
          118  124   130                                    176 
Old residue positions
 
                             112                                    158 
Nucleotide substitution                          
 
T/C                                   T/C 
Amino acid substitution                     Cys/Arg                            Cys/Arg 













































) The slopes: Kε4=1.602, Kε3=-1.122, Kε2=-0.543 
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